You are here

P&T® Journal contents for April 2004


Meeting Highlights
The author summarizes trends in the development of new biotechnology agents, in consumer-driven health care, and in evidence-based medicine, along with economic factors that will affect the pharmaceutical industry.
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
Representatives from a consortium of more than 30 organizations assembled to discuss the impact of the Medicare Modernization Act, and the newly approved Drug Discount Cards, on older patients.
Vanja Sikirica, PharmD
Dr. Valuck discusses the advantages and shortcomings of the SSRIs compared with earlier antidepressant medications, with special emphasis on the new agent escitalopram oxalate (Lexapro™).
Robert Valuck, PhD, RPh
Continuing Education Credit
Dr. Ebert reviews the complicated processes of comparing antimicrobial agents and choosing the most appropriate antibiotic in clinical practice.
Steven C. Ebert, PharmD, BCPS


David Nash, MD, MBA, discusses 1 on 1health™, a Web site that provides valuable information to patients to help them understand and manage their diseases.
David B. Nash, MD, MBA
Prescription Washington
Stephen Barlas explains that the FDA’s final rule on bar coding does not help pharmacies if hospitals don’t buy scanners.
Stephen Barlas
Medication Errors
Matthew Grissinger, RPh, FASCP, presents some strategies to enable nurses to administer the right medications to the right patients.
Matthew Grissinger, RPh, FASCP
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.